<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04187820</url>
  </required_header>
  <id_info>
    <org_study_id>ZYS2019-01</org_study_id>
    <nct_id>NCT04187820</nct_id>
  </id_info>
  <brief_title>Effect of Acupuncture on Mild to Moderate Active Crohn's Disease</brief_title>
  <official_title>Effect of Acupuncture on Crohn's Disease Via the Regulation of Trp-kyn Metabolism in Brain-gut Axis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Institute of Acupuncture, Moxibustion and Meridian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Institute of Acupuncture, Moxibustion and Meridian</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the clinical effect of acupuncture on Crohn's disease (CD) and its influence on
      brain function activity and the TRY-KYN metabolism level, and to screen the brain image
      markers of acupuncture on CD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Effect of acupuncture on symptoms of CD

        2. Effect of acupuncture on brain functional activity of CD

        3. Effect of acupuncture on intestinal and plasma TRP-KYN metabolism level of CD

        4. Screen the brain image markers of acupuncture in the treatment of CD
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>Week 12</time_frame>
    <description>Crohn's disease activity index （CDAI）less than 150 and decreased more than 70</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>Week 24, 36 and 48</time_frame>
    <description>Crohn's disease activity index （CDAI） less than 150 and decreased more than 70</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Week 12, 24, 36 and 48</time_frame>
    <description>Crohn's disease activity index （CDAI） decreased more than 70</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crohn's disease activity index （CDAI）score</measure>
    <time_frame>Week 12, 24, 36 and 48</time_frame>
    <description>The mean change in CDAI from baseline. The higher the score, the worse the condition. Greater than 0, no upper limit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory test</measure>
    <time_frame>Week 12, 24, 36 and 48</time_frame>
    <description>serum C-reactive protein (CRP) level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory test</measure>
    <time_frame>Week 12, 24, 36 and 48</time_frame>
    <description>Erythrocyte sedimentation rate (ESR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory test</measure>
    <time_frame>Week 12, 24, 36 and 48</time_frame>
    <description>Platelet count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory bowel disease questionnaire (IBDQ)</measure>
    <time_frame>Week 12 and 24</time_frame>
    <description>The mean change in IBDQ from baseline. The higher the score, the worse the condition.The score is range from 32 to 224.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crohn's disease endoscopic index of severity (CDEIS)</measure>
    <time_frame>Week 48</time_frame>
    <description>The mean change in CDEIS from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital anxiety and depression scale (HADS)</measure>
    <time_frame>Week 12 and 24</time_frame>
    <description>The mean change in HADS from baseline. The higher the score, the more serious the disease. The depression and anxiety score is range from 0 to 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of recurrences</measure>
    <time_frame>Week 48</time_frame>
    <description>Defined as CDAI &gt; 150 and increase ≥ 70 points or need to adjust drug to control disease condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain functional and structural changes</measure>
    <time_frame>Week 12</time_frame>
    <description>measured by functional MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and intestinal TRP-KYN metabolism level</measure>
    <time_frame>Week 12</time_frame>
    <description>Plasma and intestinal Indoleamine2,3dioxygenase 1 （IDO1）level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and intestinal TRP-KYN metabolism level</measure>
    <time_frame>Week 12</time_frame>
    <description>Plasma and intestinal Tryptophan (TRP) level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and intestinal TRP-KYN metabolism level</measure>
    <time_frame>Week 12</time_frame>
    <description>Plasma and intestinal kynurenine （KYN）level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and intestinal TRP-KYN metabolism level</measure>
    <time_frame>Week 12</time_frame>
    <description>Plasma and intestinal kynurenic acid （KYNA） level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and intestinal TRP-KYN metabolism level</measure>
    <time_frame>Week 12</time_frame>
    <description>Plasma and intestinal quinolinic acid (QUIN) level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and intestinal TRP-KYN metabolism level</measure>
    <time_frame>Week 12</time_frame>
    <description>Plasma and intestinal IFN-gamma level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and intestinal TRP-KYN metabolism level</measure>
    <time_frame>Week 12</time_frame>
    <description>Plasma and intestinal IL-1beta level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and intestinal TRP-KYN metabolism level</measure>
    <time_frame>Week 12</time_frame>
    <description>Plasma and intestinal IL-18 level</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intestinal Disorder</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Acupuncture group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving acupuncture and mild moxibustion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>acupuncture</intervention_name>
    <description>Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. In the acupuncture group, Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustIon.</description>
    <arm_group_label>Acupuncture group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. aged 16-70;

          2. patients with mild or moderate active disease (150 ≤ CDAI &lt; 450);

          3. patients who are not responsive, intolerant, dependent or refused to use at least
             mesalazine, glucocorticoid, immunomodulator (azathioprine, methotrexate), anti TNF
             alpha preparation;

          4. patients were not taking medication or were only taking one or more of the following
             drugs: [prednisone ≤15mg/d, azathioprine (≤1mg/kg/d), methotrexate (≤15mg/w) or
             mesalazine (≤4g/d)] and prednisone was used for at least 1 month, while azathioprine,
             methotrexate or mesalazine was used for at least 3 months;

          5. those who did not use anti-TNF alpha and other agents within 3 months before entering
             the study;

          6. those who have never experienced acupuncture;

          7. patients signing informed consent.

        Exclusion Criteria:

          1. patients who are recently pregnant or in pregnancy or lactation;

          2. patients with serious organic diseases;

          3. patients diagnosed as psychosis;

          4. patients who take antibiotics, probiotics, traditional Chinese medicine and other
             drugs at the same time, or who suffer from multiple diseases and need to take other
             drugs for a long time, and may affect the observation of the efficacy of this trial;

          5. severe skin diseases (such as erythema nodosum, pyoderma gangrenosum, etc.), eye
             diseases (such as iritis, uveitis, etc.), thromboembolic diseases and other serious
             extraintestinal manifestations;

          6. there are serious intestinal fistula, abdominal abscess, intestinal stenosis and
             obstruction, perianal abscess, gastrointestinal hemorrhage, intestinal perforation and
             other complications;

          7. patients with short bowel syndrome who have undergone abdominal or gastrointestinal
             surgery in the past half a year;

          8. there are skin diseases or defects in the selected area of acupuncture and moxibustion
             that cannot be performed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huangan Wu, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Research Institute of Acupuncture and Meridian</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunhui Bao, MD, PhD</last_name>
    <phone>+862164395973</phone>
    <email>baochunhui789@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Research Institute of Acupuncture and Meridian</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunhui Bao, Doctor</last_name>
      <phone>+862164395973</phone>
      <email>baochunhui789@126.com</email>
    </contact>
    <investigator>
      <last_name>Huangan Wu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guona Li</name>
      <address>
        <city>Shanghai</city>
        <zip>2000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guona Li</last_name>
      <phone>+862465161782</phone>
      <email>liguonaaa@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 1, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>December 22, 2019</last_update_submitted>
  <last_update_submitted_qc>December 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acupuncture</keyword>
  <keyword>Crohn's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

